key: cord-0916072-wrxmx245
authors: Hughes, David M.; Mordino, Jason
title: Pharmacist responsiveness and readiness for oral antivirals for COVID-19: a rebuttal to the AMA statement regarding the Biden administration’s test-to-treat plan
date: 2022-04-01
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2022.03.023
sha: 972ae9cf1e909c3accfeda19356ecc546296ba8c
doc_id: 916072
cord_uid: wrxmx245

On March 4, 2022, the American Medical Association (AMA) released a statement in response to the Biden administration’s plan of a test-to-treat plan allowing pharmacists to serve as locations to test and provide prescriptions for oral antivirals for treatment of COVID-19 after a positive test result. The statement by the AMA contradicts and underrepresents the impact pharmacists have in clinical practice. Pharmacists have been a crucial part of many efforts including mass vaccination efforts and furnishing of prescriptions for other complex disease states (e.g., PrEP and PEP therapy). Furthermore, health systems have proven novel approaches to mitigate operational and clinical barriers to COVID-19 therapies may offset the increased demand needed by communities. Herein, this commentary will discuss a viewpoint and counterpoint to the statement put out by the AMA, with a focus on pharmacists.

to the Biden administration's plan of a test-to-treat plan allowing pharmacists to serve as 4 locations to test and provide prescriptions for oral antivirals for treatment of COVID-19 after a 5 positive test result. The statement by the AMA contradicts and underrepresents the impact 6

pharmacists have in clinical practice. Pharmacists have been a crucial part of many efforts 7

including mass vaccination efforts and furnishing of prescriptions for other complex disease 8

states (e.g., PrEP and PEP therapy). Furthermore, health systems have proven novel approaches 9

to mitigate operational and clinical barriers to COVID-19 therapies may offset the increased 10 demand needed by communities. Herein, this commentary will discuss a viewpoint and 11 counterpoint to the statement put out by the AMA, with a focus on pharmacists. 12

On March 4, 2022, the American Medical Association (AMA) released a statement in response 13

to the Biden administration's decision incorporating a pharmacy-based clinic component to the 14 test-to-treat (TTT) plan to help combat COVID-19 1, 2 . While the AMA's statement highlights 15 several complexities, it diminishes the collaborative approach in the healthcare field amongst 16 physicians and advanced practice providers (APPs) such as pharmacists, physician assistants, 17

and nurse practitioners. The AMA states that this approach "…oversimplifies challenging 18

prescribing decisions by omitting knowledge of a patient's medical history, the complexity of 19 drug interactions, and managing possible negative reactions." This assumes an approach of "test 20 and dispense," without a careful history and review by pharmacists. Pharmacists have 21 demonstrated their competence at handling complexity and making sound therapeutic decisions 22

that optimize patient care and provide rapid access to appropriate medications in community and 23

hospital settings. While all APP disciplines are capable of taking detailed and complete medical 24 history, this commentary will focus solely on the pharmacist's role.

Pharmacists continue to be referred to as one of the most accessible and trusted health care 27 professionals to communities across the United States. As part of the mandated doctoral training 28

in the profession, pharmacists are trained to evaluate patient medical history and complicating 29 factors pursuant to pharmacotherapy treatment decisions including drug-drug interactions 30

(DDIs), side effect management, and adherence barriers to therapy. In contrast to the AMA's 31 statement, the incorporation of pharmacists into the medication reconciliation process has led to 32 decreased medication errors in the health system, decreased adverse drug events, and improved 33 interdisciplinary communication across professions 3-5 . Pharmacists are adept because they have 34

had to overcome lack of access to medical charts in the community. . Models of expanding chart 35

access to community pharmacists have demonstrated improved patient care, education and care 36 coordination 6-9 . Rather than advocate against allowing drug experts to support direct patient care, 37

the AMA should be advocating to support nationalized chart access and increased transparency 38

to community pharmacists for improved patient safety.

In addition to accurate medication and medical history, the pharmacist scope has continued to 41 expand into areas including more complex therapeutic drug management, including areas such as 42 human immunodeficiency virus (HIV). In 2019, the state of California authorized a bill allowing 43

pharmacists to furnish pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), 44

which include many complex drug-drug interactions, dosing concerns, and toxicity that require a 45 thorough medical history 10 .While pharmacists do not have independent authority to order and 46 perform wide ranging and routine tests, states have granted drug therapy management protocols 47

to meet a public demand. In the state of Oregon, pharmacists have the ability to perform point-48

of-care (POC) testing for HIV when furnishing PEP therapy. Additionally, in order to furnish 49

PrEP therapy, the pharmacist must verify laboratory tests associated with PrEP therapy in 50 addition to a comprehensive medication/medical history 11 . As with the anti-retroviral (ARV) 51 therapies used for PEP and PrEP, COVID-19 oral antivirals require clinical interviewing for a 52 robust medical history and careful consideration for therapy selection prior to furnishing 53

prescriptions. In addition to PrEP and PEP, pharmacists have been extensively involved with 54 dispensation of oral contraception and furnishing prescriptions related to Streptococcal and 55

influenza respiratory infections, Through these similarly complex therapeutic initiatives [PrEP 56

and PEP], pharmacists have demonstrated their success to provide complex clinical services 57 across community practice despite multiple challenges. 58 59

The experience by our medical center [and pharmacy department] directly refutes the statement 60 put out by the AMA by demonstrating that pharmacists possess clinical knowledge required for 61 complex disease state management and furnishing oral antivirals for COVID-19. Our health 62 system, as with many others, were challenged by a rapid surge of COVID-19 patients. State and 63

federal agencies released guidelines to serve as a framework to prioritize the most vulnerable 64 patients with a limited drug supply of oral antivirals for COVID-19. The pharmacy department at 65 our medical center recognized the need to implement a novel multidisciplinary system to rapidly 66 increase appropriate prescribing, dispensing, and access to COVID-19 oral antiviral therapies to 67 combat the Omicron surge. Outpatient pharmacists [at dispensing pharmacies] provided patient-68 centered education and coordination of care services for to dispense over 100 prescriptions to our 69 community. They validated all contraindications DDIs, and dosing implications adherent to state 70 and federal guidance. This includes both health-system associated providers that have readily 71

accessible electronic medical record (EMR) information but also providers at outside practices 72 that would require comprehensive medical history prior to dispensation. Ambulatory pharmacists 73 at our center work under a collaborative scope of practice agreement with an attending physician 74

supervisor. These agreements allowed pharmacists to write orders and monitor patients 75 consistent with the attending physicians' specialized practice area. This expansion increased 76

prescribing by over 250% in the following two weeks. Additionally, ambulatory pharmacists 77 performed follow-up phone calls to assess adherence, toxicity, and ongoing symptoms of 78 COVID-19 as a means to offset physician resources.

Subsequently, pharmacists developed a pilot service within our emergency department to screen 81 COVID-19 positive patients for eligibility for treatment and prescribe appropriate therapy as 82

granted under a scope of practice agreement with infectious diseases physicians (118 patients).

Pharmacists were able to provide prescriptions to patients but also educate providers on 84 management of complex DDIs and improve functionalities within the EMR to lead the 85 refinement of systematic processes. The infrastructure and services provided by our pharmacy 86 teams were well supported by hospital and clinic leadership who recognize pharmacists' 87 competency to make COVID-19 therapies safe and more accessible. The above initiative is 88

another example of pharmacists' demonstrating their adaptability in clinical practice and ability 89

to manage complex therapeutic decisions and prescribing COVID-19 oral antivirals.

This initiative and other models [at other areas of pharmacy practice] serve to supplement 92 physicians as opposed to replacing clinical services with the current TTT plan proposed by the 93

Biden administration. As many healthcare professionals are at capacity, including physicians, our 94 pilot using pharmacists' services demonstrate the utility of a collaborative approach to safely 95 prescribing and dispensing COVID-19 oral antivirals. Additionally, the advancement of the 96 pharmacist's scope to extend clinical services to the HIV population further supports this 97 rebuttal. However, the challenge faced by communities' pharmacists will be primarily 98

operational. As pharmacists have been a core contributor in the expansion of administration of 99 COVID-19 vaccines, the additional clinical tasks will require support from senior leadership of 100 respective pharmacies. While the current TTT plan does not grant prescriptive authority to 101

pharmacists, having pharmacists adjacent to these clinics renders rapid clinical support and 102 integrated team work readily available. With a higher level of mutual collaboration across 103 J o u r n a l P r e -p r o o f

AMA statement on Administration's 119 test-to-treat COVID-19 plan

Frequency, type and 124 clinical importance of medication history errors at admission to hospital: a systematic review

Impact of a Pharmacy-Led Medication Reconciliation 127 Program

Program Reduces Adverse Drug Events and Improves Satisfaction in a Community Hospital

Enhancing Practice Efficiency and 132

Patient Care by Sharing Electronic Health Records

Are community-134 based pharmacists underused in the care of persons living with HIV? A need for structural and 135 policy changes

Pharmacists' familiarity, utilization, and beliefs about 138

Health Information Exchange: a survey of pharmacists in an Indiana pharmacy organization

Pharmacists' use of electronic health records: Silent 141 leaders no more

Expanding PrEP and PEP Access in California

Pharmacist Prescribed PrEP 148 and PEP in Oregon

healthcare disciplines, pharmacists would be able to apply existing clinical skills to deliver care 104 to more patients.

Clinical complexities of pharmacotherapy, such as oral antivirals to COVID-19, do not limit the 107 pursuit of the administration's TTT program. Rather the AMA, governmental administration, and 108 pharmacy organizations should encourage the expansion of pharmacist prescriptive authority to 109include COVID-19 antivirals, advocate for enhanced chart access for community pharmacists, 110and advocate for more interdisciplinary collaboration. Pharmacists have shown themselves to be 111 the drug experts capable of complex medical and medication history taking, medication 112prescribing and education. Their eclectic ability to provide safe, thoughtful, and educated 113 recommendations for pharmacotherapy have improved access to community patient populations. 114 115 116